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Abstract
Introduction We aimed to assess the value of a second MR
scan in the radiological diagnosis of dementia.
Methods One hundred twenty subjects with clinical follow-
up of at least 1 year with two scans were selected from a
cognitive disorders clinic. Scans were reviewed as a single
first scan (method A), two unregistered scans presented side-
by-side (method B) and a registered pair (method C). Scans
were presented to two neuroradiologists and a clinician
together with approximate scan interval (if applicable) and
age. Raters decided on a main and subtype diagnosis.
Results There was no evidence that differences between
methods (expressed as relative odds of a correct response)
differed between reviewers (p=0.17 for degenerative
condition or not, p=0.5 for main diagnosis, p=0.16 for
subtype). Accordingly, results were pooled over reviewers.
For distinguishing normal/non-progressors from degenera-
tive conditions, the proportions correctly diagnosed were
higher with methods B and C than with A (p=0.001, both
tests). The difference between method B and C was not
statistically significant (p=0.18). For main diagnosis, the
proportion of correct diagnoses were highest with method C
for all three reviewers; however, this was not statistically
significant comparing with method A (p=0.23) or with
method B (p=0.16). For subtype diagnosis, there was some
evidence that method C was better than method A (p=0.01)
and B (p=0.048).
Conclusions Serial MRI and registration may improve
visual diagnosis in dementia.
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Introduction
Dementia is one of the leading global health and socio-
economic problems [1]. Many diseases can cause dementia,
but Alzheimer’s disease (AD) is the most common [2, 3].
Vascular dementia and dementia with Lewy bodies (DLB)
are the next most common [2, 3] whilst frontotemporal
lobar degeneration (FTLD) is the third most common
dementing disease under 65 years [4].
In dementia, a definitive diagnosis requires histological
examination of brain tissue, and clinical diagnosis may be
difficult, particularly in the early stages. The hallmarks of
AD are intracellular neurofibrillary tangles, extracellular
amyloid plaques and cerebral atrophy, which increase with
disease severity [5]. Clinically, AD typically presents with
amnestic problems, but there are a range of differing
presentations including posterior and anterior variants [6]
when subjects can present with atypical symptoms such as
visual problems and behavioural disturbances, respectively.
DLB can occur in a pure form or can co-exist with AD
pathology, and similarly mixed AD/vascular pathologies are
seen at autopsy in approximately 30% of clinically
diagnosed AD cases [2]. FTLD may be caused by several
different neurodegenerative pathologies most commonly
with tau- or ubiquitin-positive neuronal inclusions [7].
According to clinical presentation, FTLD can be subdivided
into language variants such as semantic dementia (SD) and
progressive non-fluent aphasia (PNFA) and behavioural
variant FTLD (bvFTD) [8].
Whilst definitive diagnosis of the neurodegenerative
dementias requires histology, the characteristic pattern of
neuronal loss is reflected in the pattern of regional brain
atrophy. There is thus a great interest in using imaging to
improve or support clinical diagnoses. Recently, medial
temporal lobe atrophy has been included in new proposed
diagnostic criteria for AD [9], whilst focal frontal and/or
temporal atrophy are part of diagnostic consensus criteria for
FTLD [10]. The different clinical presentations of FTLD are
associated with different patterns of atrophy; SD patients
typically having predominant often asymmetric temporal
lobe atrophy; PNFA having (left) perisylvian atrophy whilst
preferential frontal atrophy is seen in bvFTD. Despite these
characteristic associations, there is some overlap and some
dissociation in a number of cases.
Visual inspection of the pattern of atrophy on MRI is
probably the most common imaging assessment used to
diagnose specific diseases causing dementia in clinical
practice. Usually, a single scan is performed, but in some
cases, a further scan is taken to assess progression and
clarify diagnosis. Positional matching (registration) of scans
has been a valuable research tool in understanding the
natural history of neurodegenerative diseases [11]. Regis-
tration allows different analyses: visual analysis and
assessment of progression, calculation of atrophy [12, 13],
estimation of atrophy location [14, 15] and estimation of
volume changes in brain sub-regions [16]. Increased
atrophy rates of whole brain and sub-regions are predictive
of clinical progression to a dementia diagnosis [17].
However, the value of serial imaging and registration in a
clinical setting is not well understood.
We aimed to assess added diagnostic value of performing
a second scan and whether registration of the second scan to
baseline would improve diagnostic accuracy further. Visual
diagnosis was compared with (a) clinical diagnosis and (b)
pathological confirmation where available.
Materials and methods
Subject selection
This retrospective study was conducted using subjects
referred to the specialist cognitive disorders clinic at the
National Hospital for Neurology and Neurosurgery, who
had more than one MRI scan, had attended clinic more than
twice and remained in follow-up for 12 months or more.
Three hundred and one subjects with at least two MRI
scans were identified. In addition, subjects known to have
either pathological or genetic confirmation of disease and
two scans were included.
Clinical notes were reviewed in order to categorise the
subjects according to their final diagnosis (with final diagnosis
being either the last clinical or pathological diagnosis).
Categories included those with a non-progressive or degener-
ative condition and normals and those with progressive
degenerative diseases: AD [18], FTLD [10] or other. Subjects
were excluded if a diagnosis was not stated. This resulted in
120 subjects with two usable MRI scans and a clinical,
genetic or pathological diagnosis. Some of the subjects have
been included in different studies [19–21].
Each subject was given an identification number, and
this number replaced subject names on all scans. The date
of the scan remained unedited. Baseline and follow-up
images were co-registered using 12 degrees of freedom [22]
and differential bias correction [23] to reduce intensity non-
uniformity differences.
Presentation of scans
Scans were reviewed as a single first scan (method A), the
two unregistered presented side-by-side (method B) and the
registered pair (method C). In order to minimise bias, a
design based on the three-period cross-over design [24, 25]
was utilised to determine the order in which scans were
presented to the reviewers. Stratified by final diagnosis,
subjects were randomised into six groups of 20 subjects.
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Reviewers were presented with scans in 18 blocks each
including results from a single group using a particular
methodology (A, B or C). The six groups were distin-
guished by the order in which the methodologies were
reviewed (ABC, ACB, BAC, BCA, CAB or CBA). A
second randomisation was used to order the subjects within
each group (this order remained the same for each
methodology). Finally, the ordering of the groups was
determined using a restricted randomisation that ensured
that the first three groups selected made up a Latin Square,
as did the final three groups. The selected ordering was
“CBA”, “ACB”, “BAC”, “ABC”, “CAB” and “BCA”.
Hence, the reviewer was first presented with 20 registered
scan pairs (method C) from the “CBA” group, then with 20
single scans (method A) from the “ACB” group and so on.
Subjects and methods were viewed independently by a
clinician (neurologist in training with 2 years experience at
the Dementia Research Centre) and two neuroradiologists.
Only the approximate scan interval (if method B or C) and
age at first scan were given. The reviewer had to decide on
a main and specific (subtype) diagnosis. Main diagnoses
included: AD, FTLD, normal, non-specific and other.
Subtype diagnoses were typical and posterior variant for
AD and behavioural variant (bv), temporal variant (tv) and
PNFA for FTLD. A certainty rating of diagnosis: low,
medium or high, was also made. If two scans were
presented, the reviewer had to decide whether progressive
pathological atrophy was present. The start and end time of
each 20 scan session was recorded to estimate assessment
time by method. Once all scans were reviewed, the first 20
subjects were reviewed again in the same order using each
method to provide a measure of within-rater repeatability.
Data analysis
Prior to analysis, the diagnostic categories of non-specific
and other were collapsed since specific diagnoses were
rarely recorded when “other” was used. Data analysis was
performed using STATA version 10 (STATA Corporation,
College Station, TX, USA) and SAS (SAS Institute Inc.,
Cary, NC, USA).
In the primary analysis, the (binary) outcome was whether
the four category main diagnosis (normal/non-progressor,
AD, FTLD or other pathology) was correct. A secondary
analysis merely considered whether the broad categorisation
of “normal/non-progressor” vs “degenerative condition”
(AD, FTLD and other pathology combined) was correct. In
a further secondary analysis restricted to those subjects with
AD and FTLD, the (binary) outcome was whether or not the
subtype diagnosis was correct. Since the study used a cross-
over design, conditional logistic regression was used to
account for subject-specific effects. As is standard in cross-
over trials [24, 25], all analyses were adjusted for period. For
all of these outcomes, predictor variables were (1) method,
(2) reviewer and (3) interaction of (1) and (2). A weighted
Kappa statistic was used to assess within-rater repeatability
with a main diagnosis disagreement between a normal/non-
progressive diagnosis and a neurodegenerative disease (i.e.
normal vs FTLD) weighted at zero, and within degenerative
disease disagreement (i.e. AD vs FTLD) weighted as 0.75.
For subtype analyses, disagreements across AD and FTLD
subtypes were weighted at zero, and the within AD or FTLD
disagreements (i.e. posterior vs typical for AD) were
weighted at 0.75.
As a check on the reliability of the findings, we
investigated whether there was evidence of a difference in
results according to pathological disease diagnosis. This
was performed by including interactions between method
and a “pathological” indicator.
A further set of analyses considered certainty of
diagnosis (three levels) as an ordered categorical response.
For each reviewer, a proportional odds model with subject
as a random effect [24, pp 311–313] was used to relate this
outcome variable to method, correctness of diagnosis and
their interaction (with adjustment for period effects).
Results
Details of subjects are reported in Tables 1 and 2. Those
within the category of “non-progressor” included: three
with static cognitive impairment, one monophasic illness
Table 1 Subject demographics as main diagnosis.
Normals and non-progressors AD FTLD Other
N (no with established diagnosisa) 18 (4) 56 (21) 27 (16) 19 (10)
Male/female 12/6 28/28 17/10 17/2
Mean age/years (SD) at baseline scan 58 (13) 63 (9) 61 (7) 61 (14)
Mean scan interval/months (SD) 19 (10) 16 (10) 19 (13) 17 (10)
a Established describes those subjects for whom either genetic or pathological proof of disease is available. Four normal controls include one with
a normal post mortem, two considered to be normal/depressed and one with a positive genetic test for pre-senilin 1 who remained asymptomatic
for at least 5 years
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affecting frontal lobes, two with depression, one with
vestibular dysfunction, one with a resolved monophasic
neuropsychiatric illness of unknown cause, one sleep
apnoea, one pre-senilin 1 carrier who remained asymptom-
atic 5 years after the repeat scan, one with subjective
memory impairment and one with temporal lobe epilepsy.
Those within the “other” category included: one multi-
system atrophy, three DLB, one Niemann–Pick disease type
C, six vascular dementia, one Parkinson’s disease, one
CADASIL, one subject with a frontal and temporal
presentation with atypical FTLD pathology and clinical
features, two prion disease, one with mixed vascular and
temporal lobe epilepsy and two with progressive supra-
nuclear palsy. Two subjects in the AD category had mixed
vascular dementia and AD.
Comparison of inter-reviewer patterns
Table 3 shows the proportions of correct diagnoses for each
reviewer using each of the three methods. For each
outcome (degenerative condition or not, main diagnosis,
subtype diagnosis), the odds of a correct response differed
between the three reviewers. However, there was no
evidence that the differences between methods (expressed
as a relative odds of a correct response) differed between
reviewers (p=0.17 for degenerative condition or not, p=0.5
for main diagnosis, p=0.16 for subtype). Accordingly, we
primarily report results from a pooled analysis, adjusting
for main effects of reviewer, period and their interaction.
For distinguishing normal/non-progressors from degen-
erative conditions, the proportions correctly diagnosed were
higher with methods B and C than with A for all three
reviewers. Pooling over reviewers, the relative odds of a
correct response with method C compared with A was 4.3
(95% CI 2.2, 8.5, p<0.001). The analogous odds ratio
comparing method B with A was 2.8 (95% CI 1.5, 5.2, p=
0.001). The difference between method B and C was not
statistically significant (p=0.18). Although the global test
of interaction between reviewer and method was not
statistically significant, there were some quite large differ-
ences between reviewers. In particular, for the clinician and
neuroradiologist 1, performance with B and C was almost
identical, whilst for neuroradiologist 2, performance was
better with C.
For main diagnosis, the proportion of correct diagnoses
was highest with method C for all three reviewers.
However, neither the comparison with method A (odds
ratio=1.3, 95% CI 0.8, 2.0, p=0.23) or that with B (odds
ratio=1.4, 95% CI 0.9, 2.1, p=0.16) achieved statistical
significance. For the clinician, the percentage agreement
and weighted Kappa statistic for reliability for main
diagnosis were 73.75% and 0.38 for method A, 92.50%
and 0.75 for method B and 80.00% and 0.36 for method C,
respectively. For neuroradiologist 1, the analogous statistics
were 90.00% and 0.64 for method A, 90.00% and 0.62 for
method B and 92.50% and 0.64 for method C. For
neuroradiologist 2, the analogous statistics were 100% and
1.00 for method A, 95.00% and 0.84 for method B and
76.25% and 0.31 for method C.
For subtype diagnosis, pooling over reviewers, there was
some evidence that method C was better than method A
(odds ratio=1.9, 95% CI 1.2, 3.1, p=0.01) and B (odds
ratio=1.6, 95% CI 1.0, 2.7, p=0.048). Although the global
test of interaction between reviewer and method was non-
statistically significant, there were some quite large differ-
ences between reviewers. Most strikingly, the clinician’s
correct diagnosis rate was the same with method A as with
C, whereas for neuroradiologist 1 their rate was substan-
tially lower. For the clinician, the percentage agreement and
weighted Kappa statistic for reliability for subtype were
90.38% and 0.41 for method A, 96.67% and 0.90 for
method B and 98.33% and 0.95 for method C. Analogous
statistics for neuroradiologist 1 were 95.00% and 0.90 for
method A, 97.92% and 0.95 for method B and 87.50% and
0.71 for method C. For neuroradiologist 2, the analogous
statistics were 97.06% and 0.93 for method A, 98.44% and
0.97 for method B and 84.62% and 0.64 for method C.
Pathological/genetic proof of disease
For conditional logistic regression analyses where the
outcome was a correct main diagnosis or subtype diagnosis,
we found no evidence that the differences between the
methods (expressed as odds ratios) depended upon whether
or not there was pathological confirmation of diagnosis and
main diagnosis (p>0.5 for both outcomes, joint test of
interactions between method and a pathology-proven
indicator). For distinguishing normal/non-progressors from
AD FTLD
Typicala Posterior bv tv PNFA
N 43 13 13 11 3
Mean age/years (SD) at baseline scan 63 (10) 62 (8) 60 (9) 62 (6) 65 (5)
Mean scan interval/months (SD) 17 (10) 12 (5) 17 (14) 22 (12) 13 (5)
Table 2 Subject demographics
by subtype diagnosis.
bv behavioural variant, tv
temporal variant, PNFA
progressive non-fluent aphasia
a Typical describes AD subjects
with no mention of posterior
cortical atrophy/biparietal AD
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degenerative conditions, there was evidence (p=0.01, joint
test of interactions) that the odds ratios favouring methods
B and C over A were larger when pathology was proven
than when unproven.
Certainty of diagnosis
The distribution of diagnostic certainty for both correct and
incorrect main diagnoses in all 120 subjects is shown in
Fig. 1.
For the clinician, when a correct diagnosis was made,
there was borderline statistically significant evidence of
variation in certainty according to method (p=0.07, joint
test). Specifically, a difference in certainty was seen for
method B vs method Awith an increase in the proportion of
medium and highly certain diagnoses (p=0.03). An
analogous pair-wise comparison of method C with method
A was of borderline statistical significance (p=0.09).
Further, when the diagnosis was wrong, there was
significant variation in certainty according to method with
an increase in proportion of high certainty from methods A
to C (p=0.03). Generally, when a correct diagnosis was
made, the certainty was higher than when an incorrect
diagnosis was made.
When neuroradiologist 1 was correct, there was
significant variation in certainty by method (p=0.03, joint
test). However, when wrong, there was no evidence in
variation of certainty by method. When correct, a
difference in pattern was seen for method C vs method
Awith an increase in the proportion of medium and highly
certain diagnoses (p=0.01). An analogous pair-wise
analysis for method B vs method A was of borderline
statistical significance (p=0.09). Whether this neuroradi-
ologist was correct or incorrect with method A had little
impact on certainty; however, using both methods B and C
when a correct diagnosis was made, the certainty was also
greater.
When neuroradiologist 2 was correct, there was signif-
icant variation in certainty by method (p=0.03, joint test).
Certainty was greater with method C than with either of the
other methods. The same trend was significant (p=0.04,
joint test) when the neuroradiologist was incorrect. Gener-
ally, when a correct diagnosis was made, the certainty was
higher than when an incorrect diagnosis was made.
Timings
Table 4 shows an estimate of the assessment time in
seconds each reviewer needed to view a subject according
to method. For all reviewers, method B took longest, and
method A took shortest to view. Neuroradiologist 2 took
most time using all methods, and neuroradiologist 1 took
least time using all methods.Ta
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Discussion
This study assessed the relative value of visual assessment
of single time-point MRI and serial MRI in the radiological
diagnosis of dementia. Visual assessments were compared
with clinical diagnosis or with pathological diagnosis when
available. We found that serial imaging was useful in
determining whether a subject had a degenerative condi-
tion, with incorrect classification occurring in 16–23% of
cases with single scans, which lowered to 8–22% using
serial imaging. However, specific identification of main
diagnosis was incorrect 30–42% of the time with no
statistically significant advantage provided by serial imag-
ing. Where main diagnoses were AD and FTLD, there was
some evidence that serial imaging and, in particular,
registration improved subtype diagnosis for the reviewers.
Although non-significant, there were some differences
between reviewers in terms of their pattern of correct
subtype diagnoses according to method. For neuroradiolo-
gist 1, in particular, serial imaging and additionally
registration of the serial images increased the certainty of
diagnosis when this diagnosis was correct. For all reviewers
assessing serial images, unregistered images took longer
than registered, and both serial scan presentations were
more time consuming than the single baseline scan.
Registration is an automated procedure which often
requires little operator intervention; in this particular study,
brain to brain registration was performed using an auto-
mated registration technique [22]. This involved semi-
automated segmentation of the brain regions prior to
registration [26] taking approximately 10 min per scan.
Such processing may be unnecessary to achieve registration
of sufficient quality for reviewing serial images. Many
algorithms exist which enable registration to be performed
[12, 27–30], and these are often part of packages which
have a graphical user interface to aid non-technical staff. In
the future, it is possible that such techniques will be applied
in real time, whilst subjects are in the scanner. This will not
only provide a neuroradiologist with information at the time
of reporting but will also allow quality evaluation of serial
images.
Other studies have assessed the use of different techniques
in diagnosing subjects or predicting group membership.
Visual rating such as medial temporal atrophy ratings scales
[31] has been shown to distinguish clinically diagnosed AD
patients from controls with a sensitivity of approximately
85% for a specificity of 80% [32]. Width of temporal lobe
on MRI has been shown to have a sensitivity of 86% and a
specificity of 93% when discriminating AD subjects from
controls [33]. Pair-wise differences between controls and
AD, SD and bvFTD patient groups using visual ratings of
multiple regions have also been shown [34]. Volumetric
analysis has been shown to discriminate between controls
and AD subjects [35] and predict the subsequent decline of
those only mildly affected [17]. Differences in atrophy
patterns have been shown between AD and FTLD
(semantic dementia) subjects with those with semantic
Neuroradiologist 2
Neuroradiologist 1
Clinician
C
B
A
C
B
A
C
B
A
low and correct low and incorrect
medium and correct medium and incorrect
high and correct high and incorrect
Method
0%
0% 100%
100%
0%
0%
100%
100%
37 45
5521
5628
13 31 26
402512
40325
11 24 42
43247
57175
25^ 11
‘ 28 15
17 19
9 24 17
8 21 14
7 21 15
9 20 14
16 11 19
6 12 23
Low, medium and high relates to level of certainty which is expressed as a percentage of total correct and 
incorrect answers. Correct and incorrect relates to whether the main diagnosis was correct.  Numerators are 
shown over the colour bars apart from: ^=2, ‘=1.
Fig. 1 Distribution of
diagnostic certainty according to
correctness and reviewer
Table 4 Mean estimate of the amount of time in seconds each subject
was reviewed according to method and reviewer (mean represents
total time taken over six viewing sessions per method/120).
Clinician Neuroradiologist 1 Neuroradiologist 2
Method A, single 94 59 103
Method B, serial
unregistered
138 110 155
Method C, serial
registered
112 80 140
992 Neuroradiology (2010) 52:987–995
dementia having a more asymmetric (right volume>left
volume) and more anterior presentation than AD [36, 37].
More complex techniques such as cortical thickness
analysis have also been shown to differentiate AD subjects
from controls [38].
The strengths of this study are that the images were
obtained retrospectively from real clinical data of varying
quality with a variety of clinical diagnoses which mimics a
genuine clinical situation. The size of this serial imaging
dataset was large containing many subjects with proven
diagnoses. The design utilised principles from that of cross-
over trials to ensure that comparisons between reviewers using
different methods on the same subjects could be made without
introducing bias. This included ensuring that reviewers had a
“passive wash-out period” which was accomplished by
ensuring that the same subject twice was not reviewed twice
on the same day by the same reviewer, so that diagnosis for a
given subject was less likely to be remembered.
This study has a number of limitations. First, the
equipoise of subjects is different to many clinical settings;
subjects referred to our tertiary referral centre are often those
who are difficult to diagnose or may have relatively rare
conditions. In addition, we selected subjects with patholog-
ically or genetically confirmed diseases to increase the
certainty of diagnosis. Subjects with a post mortem or brain
biopsy are often those difficult to diagnose clinically. In
addition, in those subjects without disease confirmation, the
diagnosis was reliant on clinical notes which may have
omitted certain diagnostically relevant information. As a
result, we had a small number of cases which were classified
as “non-progressor” who may have had progressive disease
which was considered to be static in the medical notes or a
subsequent diagnosis of a progressive condition had not yet
been reached. Equally, those diagnosed with a progressive
condition such as AD may have been misdiagnosed. We also
excluded subjects for which there was an unclear diagnosis
in the clinical notes with no pathological confirmation.
Although the aim of this experiment was to compare
methods (i.e. a paired design), the absolute levels of accuracy
of diagnosis may be inflated as a result of this exclusion.
The quality of the imaging used in this study was not
always high with some of the subjects’ scans having artefacts
such as movement. Although we selected pairs of scans
performed on the same scanner, we did not control for
acquisition which in some cases changed over the scanning
interval. Differing scanners and acquisitions may have
affected the ability of the raters to determine diagnosis.
Ideally, in either a real clinical situation or a study, consistent
scanning acquisitions would be used. The inter-scan interval
also varied greatly within all groups. Although we excluded
subjects with scanning intervals of less than 4 months and
found no evidence of an effect of interval on main diagnosis,
it may be that progressive atrophic patterns are difficult to
assess at shorter intervals. We only assessed T1-weighted
imaging, and for the assessment of vascular lesions, T2-
weighted imaging would be more useful. Serial scanning in
vascular dementia may not be necessary since a diagnosis
can often be made with a single scan.
We only have results from three raters (a clinician and
two neuroradiologists), which limits our ability to general-
ise from our findings. A greater number of reviewers would
enable a more robust analysis of the influence of clinical
experience on the accuracy of diagnosis by method.
However, it is possible that the non-significant differences
between them could be explained by their different training
and expertise: The clinician is used to distinguishing
subtypes of AD and FTLD, neuroradiologist 1 is used to
comparing images side-by-side and neuroradiologist 2 has
experience of all methods. In particular, it may be that
registration improved performance of the neuroradiologists
with subtype diagnosis as different patterns of atrophy
appeared more distinct. However, more neuroradiologists
and clinicians would need to review the dataset in order to
properly assess these hypotheses. Finally, although our
study was carefully designed to mimic “real life” diagnosis,
it is a retrospective study. A prospective study, perhaps
using designs such as that adopted to assess the merits of
different screening regimes in breast cancer screening [39],
is also needed to substantiate our results in a more
controlled setting. Such a study could also incorporate
clinical histories of patients which were not provided to the
raters in our retrospective study. In addition, the added
diagnostic value of quantitative MR measures, such as
global and regional brain volumes and losses over time,
needs to be evaluated.
Conclusions
Serial scanning and registration may be of benefit in the
differential diagnosis of dementia. The extent of the
benefits may depend on the experience of the professional
making the diagnosis.
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